ROHIT SHARMA has been named the new captain of India's T20 side, replacing Virat Kohli, the cricket board said Tuesday (9) after the side were dumped out of the World Cup.
The Board of Cricket Control of India tweeted that the 34-year-old opening batsman was "named the T20I Captain for India" as it announced the squad for an upcoming tour by New Zealand.
Kohli, who took over T20I captaincy in 2017, had announced his decision to step down in September, citing his "immense workload". He remains the skipper of the one-day and Test teams.
The announcement follows news that former batting legend Rahul Dravid was replacing Ravi Shastri as coach for all formats following the World Cup, where India failed to qualify for the semifinals.
The right-handed Sharma, known for his hard hitting, made his debut in 2007 for the national team, initially playing limited-overs cricket before being included in the Test team in 2013.
Sharma also captained the Mumbai Indians to victory in the Indian Premier League (IPL) five times. Royal Challengers Bangalore, led by Kohli, have never won the title.
Kohli was also not named in the T20 squad for the New Zealand tour to give the batsman time to rest. Also left out were pace bowlers Mohammed Shami and Jasprit Bumrah as well as bowling allrounder Ravindra Jadeja.
The tour by New Zealand begins on November 17 with the first of three T20 games followed by two Test matches.
Sharma has played 116 T20 international matches, scoring 3029 runs and averages over 32.
He has amassed 9205 runs in 227 ODI’s and 3047 from 43 Test matches at an average of nearly 47.
India faced sharp criticism at home over their dismal performance in the T20 World Cup, including their humiliating defeat at the hands of arch-rival Pakistan as well as New Zealand.
But Shastri said on Monday (8) after his last game in charge after five years that the current team was "one of the great cricket teams in the history of the game".
"We might not have won this World Cup, but I think going forward we'll continue to have a strong team because the IPL throws a lot of young players into the mix. Rahul (Dravid) will have his own ideas on how to take this team forward," Shastri said.
"I think in Rohit you've got a very capable guy. He's won so many IPLs. He's the vice-captain of this side. He's waiting in the wings to take that job," Shastri added.
Kohli tweeted on Monday: "Together as one we set out to achieve our goal. Unfortunately, we fell short and no one is more disappointed than us as a side."
"The support from all of you has been fantastic and we are grateful for it all. We will aim to come back stronger and put our best foot forward."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.